{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-110907","form_type":"8-K","ticker":"OBIO","cik":"0001814114","company_name":"Orchestra BioMed Holdings, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.558600+00:00","generated_at":"2026-05-16T20:30:48.692367+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Orchestra BioMed secures $147M+ funding; BACKBEAT enrollment mid-2026","bullets":["Over $147M in strategic financing since August 2025; Ligand commits additional $31.6M for royalty interest.","Terumo pays $30M for ROFR on Virtue SAB global coronary market; total Terumo payments $65M.","BACKBEAT hypertension pivotal trial (N=500) enrollment completion expected mid-2026.","Virtue Trial (coronary ISR) IDE approved, N=740, initiated in 2H 2025.","Cash runway expected through Q4 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-110907","json":"https://secwatch.observer/filing/0001104659-25-110907.json","markdown":"https://secwatch.observer/filing/0001104659-25-110907.md","text":"https://secwatch.observer/filing/0001104659-25-110907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1814114/000110465925110907/0001104659-25-110907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1814114/000110465925110907/tm2531129d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:30:48.692367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}